Daily Stock Analysis, INSY, INSYS Therapeutics Inc, priceseries

INSYS Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.27
Close
65799000.00
High
0.38
Low
0.25
Previous Close
0.26
Daily Price Gain
65798999.74
YTD High
6.71
YTD High Date
Mar 4, 2019
YTD Low
0.14
YTD Low Date
Jun 11, 2019
YTD Price Change
65798995.65
YTD Gain
1512620589.66%
52 Week High
11.65
52 Week High Date
Aug 30, 2018
52 Week Low
0.14
52 Week Low Date
Jun 11, 2019
52 Week Price Change
65798992.34
52 Week Gain
858994678.07%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 11. 2018
6.96
Jun 26. 2018
7.65
11 Trading Days
9.93%
Link
LONG
Feb 12. 2019
4.70
Mar 6. 2019
5.82
15 Trading Days
23.81%
Link
Company Information
Stock Symbol
INSY
Exchange
NasdaqGM
Company URL
http://www.insysrx.com
Company Phone
602-910-2617
CEO
Saeed Motahari
Headquarters
Arizona
Business Address
10220 SOUTH 51ST STREET, SUITE 2, PHOENIX, AZ 85044
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001516479
About

INSYS Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients; and Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. It offers its Subsys through its incentive-based commercial sales force. The company also provides Dronabinol SG Capsule, a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. INSYS Therapeutics was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.

Description

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.